(18)F-Fluorodeoxyglucose PET/MR Imaging in Lymphoma.
(18)F-Fluorodeoxyglucose (FDG) PET/MR imaging is feasible for initial staging and therapy response assessment in lymphoma. Although FDG PET/MR imaging is equivalent to FDG PET/CT for initial staging of lymphoma, not enough data are available with regard to other indications yet. Diffusion-weighted MR imaging is a promising addition to FDG PET/MR imaging, but has not been evaluated systematically.
Department of Radiology, Dresden University Hospital, Fetscherstr. 74, Dresden 01307, Germany. Electronic address: ivan.platzek@uniklinikum-dresden.de.
Ivan
I
Platzek
D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D064847:Multimodal Imaging / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity
D019275:Radiopharmaceuticals
FDG; Lymphoma; PET/MR imaging; Recurrence; Staging